Dopamine, but Not Norepinephrine or Serotonin, Reuptake Inhibition Reverses Motor Deficits in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2002-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/jpet.102.039743PMID 12438514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP‐treated and levodopa‐primed common marmosets

  2002cited by this paper
• The SSRI, Citalopram, Improves Bradykinesia in Patients With Parkinson's Disease Treated with L-Dopa

  2002cited by this paper
• Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum

  2001influential reference
• Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms

  2000cited by this paper
• Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys

  2000cited by this paper
• Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in mptp-treated monkey

  1999cited by this paper
• Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway.

  1999influential reference
• Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

  1998cited by this paper
• Sertraline induced parkinsonim. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism

  1998cited by this paper
• Entacapone enhances levodopa‐induced reversal of motor disability in MPTP‐treated common marmosets

  1997cited by this paper
• Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study

  1997cited by this paper
• Problems with current pharmacologic treatment of Parkinson's disease.

  1997cited by this paper
• Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats.

  1995cited by this paper
• Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation

  1995cited by this paper
• Levodopa-induced dyskinesias are improved by fluoxetine

  1995cited by this paper
• A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

  1994cited by this paper
• A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.

  1994cited by this paper
• A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

  1994cited by this paper
• Clearance of Exogenous Dopamine in Rat Dorsal Striatum and Nucleus Accumbens: Role of Metabolism and Effects of Locally Applied Uptake Inhibitors

  1993cited by this paper
• Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists.

  1991cited by this paper
• Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats byα1 as compared toα2 agonists and antagonists

  1991cited by this paper
• In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis

  1990cited by this paper
• Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

  1986cited by this paper
• Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism.

  1986cited by this paper
• Behavioral aspects of serotonin-dopamine interaction in the monkey.

  1985cited by this paper
• Bupropion in Parkinson's disease

  1984cited by this paper
• Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.

  1984influential reference
• 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.

  1984cited by this paper
• Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.

  1984cited by this paper
• Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake.

  1984influential reference
• A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1983influential reference
• Mazindol in the treatment of Parkinson's disease.

  1983cited by this paper
• Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin.

  1983cited by this paper
• Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

  1983cited by this paper
• Nomifensine: effect in Parkinsonian patients not receiving levodopa.

  1981cited by this paper
• Nomifensine in Parkinson's disease.

  1977cited by this paper
• Nomifensine in parkinsonism.

  1977cited by this paper
• Nomifensine in parkinsonism.

  1976cited by this paper
• dl-N-methyl-3-(o-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for uptake of norepinephrine into rat brain synaptosomes and heart.

  1975cited by this paper
• Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.

  1960cited by this paper
• Parkinson's disease

  1940cited by this paper

• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• Combining physical & cognitive training with iPSC-derived dopaminergic neuron transplantation promotes graft integration & better functional outcome in parkinsonian marmosets.

  2024cites this paper
• Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.

  2023cites this paper
• Implications for Combination Therapy of Selective Monoamine Reuptake Inhibitors on Dopamine Transporters

  2023cites this paper
• Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence

  2021cites this paper
• An investigation into the antidyskinetic and reinforcing effects of UWA-101 in Sprague Dawley rats

  2020cites this paper
• The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results

  2020cites this paper
• Bupropion-associated movement disorders: A systematic review

  2020cites this paper
• Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson’s disease

  2018cites this paper
• Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey

  2018influential citation
• Non-human primate models of PD to test novel therapies

  2018cites this paper
• Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.

  2017cites this paper
• Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of Nonhuman Primate Studies and Clinical Trials

  2016influential citation
• Human behavioral assessments in current research of Parkinson's disease.

  2016cites this paper
• Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.

  2016cites this paper
• Animal behavioral assessments in current research of Parkinson's disease.

  2016cites this paper
• Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.

  2016cites this paper
• Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset.

  2015cites this paper
• The many different faces of major depression: it is time for personalized medicine.

  2015cites this paper
• Monoamine Reuptake Inhibitors in Parkinson's Disease

  2015influential citation
• Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

  2015cites this paper
• haracterization of long-term motor deficits in the 6-OHDA model of arkinson ’ s disease in the common marmoset

  2015cites this paper
• Advances in Electrochemical Biosensing Using Boron Doped Diamond Microelectrode

  2015cites this paper
• Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care

  2015cites this paper
• UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

  2014cites this paper
• Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease.

  2014cites this paper
• Adenosine A2A receptor as a drug discovery target.

  2014cites this paper
• RESTORATION OF MOTOR AND NON-MOTOR FUNCTIONS BY NEUROTROPHIC FACTORS IN NONHUMAN PRIMATES WITH DOPAMINE DEPLETION

  2013cites this paper
• Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082

  2013cites this paper
• Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.

  2012cites this paper
• Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion.

  2012cites this paper
• Neurotoxin-based models of Parkinson's disease.

  2012cites this paper
• A novel MDMA analogue, UWA‐101, that lacks psychoactivity and cytotoxicity, enhances l‐DOPA benefit in parkinsonian primates

  2012cites this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cites this paper
• Adenosine A(2A) Receptor Antagonists and Parkinson's Disease.

  2011cites this paper
• Excessive Daytime Sleepiness in Patients with Parkinson’s Disease

  2011cites this paper
• Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time

  2011influential citation
• The marmoset as a model of aging and age-related diseases.

  2011cites this paper
• Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited

  2011cites this paper
• A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets

  2011cites this paper
• A medicinal chemistry investigation of 3,4-Methylenedioxymethamphetamine (MDMA)

  2011cites this paper
• The MPTP-Treated Primate, with Specific Reference to the Use of the Common Marmoset ( Callithrix jacchus )

  2011cites this paper
• In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.

  2010cites this paper
• From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease.

  2009cites this paper
• In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Δ3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L.)

  2009cites this paper
• Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract.

  2008cites this paper
• Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398

  2008cites this paper
• Contribution of the mGluR 7 receptor to antiparkinsonian-like effects in rats : a behavioral study with the selective agonist AMN 082

  2007cites this paper
• Parkinson's disease, smoking, and gender

  2007cites this paper
• Bupropion‐induced parkinsonism

  2007cites this paper
• Fabrication, characterization, and application of boron-doped diamond microelectrodes for in vivo dopamine detection.

  2007cites this paper
• Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

  2007cites this paper
• Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo

  2006influential citation
• Excessive daytime sleepiness and unintended sleep in Parkinson’s disease

  2006cites this paper
• Gamma Hydroxybutyrate (GHB): mechanisms of central nervous system toxicity.

  2006cites this paper
• Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?

  2006cites this paper
• Dopamine transporter ligands: recent developments and therapeutic potential.

  2006cites this paper
• Drugs in development for Parkinson's disease: an update.

  2006cites this paper
• Levodopa-induced dyskinesia in Parkinson’s disease

  2005cites this paper
• Dopamine Uptake Inhibitor-Induced Rotation in 6-Hydroxydopamine-Lesioned Rats Involves Both D1 and D2 Receptors but Is Modulated through 5-Hydroxytryptamine and Noradrenaline Receptors

  2005cites this paper
• Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates

  2005cites this paper
• Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?

  2005cites this paper
• Marmoset monkey models of Parkinson's disease: which model, when and why?

  2005cites this paper
• Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6‐hydroxydopamine lesioned rat without sensitizing motor behaviours

  2005cites this paper
• The dopamine transporter: Importance in Parkinson's disease

  2004cites this paper
• Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons

  2004cites this paper
• The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP‐treated primates

  2004cites this paper
• Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

  2004cites this paper
• Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat

  2003cites this paper
• D‐deprenyl protects nigrostriatal neurons against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurotoxicity

  2003cites this paper
• Sleepiness and unintended sleep in Parkinson’s disease

  2003cites this paper
• Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates.

  2002cites this paper